Síndrome colestásico como forma de presentación de linfoma no Hodgkin. Reporte de un caso pediátrico / Cholestatic syndrome as a presentation of non-Hodgkin lymphoma. A pediatric case report

La ictericia colestásica se debe a la alteración de la secreción de bilirrubina conjugada; es una de las posibles causas la alteración del flujo biliar por obstrucción de la vía biliar extrahepática. El linfoma es la tercera neoplasia más frecuente en pediatría, mientras que los tumores pancreáticos son poco frecuentes y, en su mayoría, lesiones benignas. Las manifestaciones clínicas de los tumores de localización retroperitoneal son poco específicas y suelen ser tardías, por lo que la sospecha clínica debe ser alta. El objetivo del siguiente trabajo es presentar el caso de un niño de 7 años con síndrome colestásico en el que se halló un tumor en la cabeza del páncreas que comprimía la vía biliar extrahepática. El diagnóstico del tumor fue linfoma no Hodgkin (LNH). Se destaca la infrecuencia de este tumor en esta localización en la edad pediátrica

Cholestatic jaundice is due to an alteration in conjugated bilirubin secretion; a possible cause is an altered bile flow resulting from an obstruction of the extrahepatic bile duct. A lymphoma is the third most common neoplasm in pediatrics, while pancreatic tumors are rare and mostly benign. The clinical manifestations of retroperitoneal tumors are not very specific and are usually late, so a high level of clinical suspicion is required. The objective of this study is to describe the case of a 7-year-old boy with cholestatic syndrome with a tumor in the head of the pancreas compressing the extrahepatic bile duct. The tumor diagnosis was non-Hodgkin lymphoma (NHL). It is worth noting that the presence of a tumor in this location in pediatric age is uncommon

Pérdida de agudeza visual progresiva en paciente con proptosis. Caso clínico y revisión de la literatura / Progressive visual impairment in a patient with proptosis. Case report and review of the literature.

Introducción: a raíz del siguiente reporte de caso clínico se pretende repensar el diagnóstico diferencial de los tumores orbitales y revisar la literatura existente al respecto. Caso: paciente de 54 años, fumadora, acude a nuestro centro por una pérdida de agudeza visual progresiva de dos años de evolución en el ojo derecho, que se acompañaba de proptosis. Las pruebas de imagen basadas en resonancia magnética y tomografía por emisión de positrones ­ tomografía computarizada (PET-TC) realizadas describían una lesión intraconal derecha de morfología indefinida, que rodeaba el nervio óptico. El estudio inmunohistoquímico y molecular anatomopatológico confirmó la sospecha de síndrome linfoproliferativo extranodal de bajo grado. Discusión: el manejo endoscópico de estas lesiones puede resultar en una menor comorbilidad en comparación con el abordaje externo tradicional. El papel de la cirugía radica en la obtención de una muestra de la lesión que permita un correcto diagnóstico. Conclusiones: el abordaje multidisciplinar con oftalmólogos, hematólogos y expertos en radioterapia permite obtener buenos resultados quirúrgicos y clínicos en la inmensa mayoría de casos.

Introduction: as result of the following clinical case report, we intend to review the differential diagnosis of orbital tumors and review the existing literature in this regard. Case report: a 54-year-old smoking patient, consulted to our department due to a progressive visual impairment over the last two years in her right eye. She presented proptosis in her clinical examination. Imaging studies based on MRI and PET-CT described a right intraconal lesion with an undefined morphology surrounding the optic nerve. Orbital tumors differential diagnosis is delicate. Nevertheless, Non-Hodgkin lymphomas followed by metastasis are the two most common found in this location. The immunohistochemistry and molecular studies, confirmed the suspected diagnosis of extranodal low-grade lymphoproliferative syndrome. Discussion: endoscopic management of these lesions may result in a lower comorbidity compared to traditional external approaches. Role of surgery lays in obtainment of a quality sample which allows a proper diagnosis. Conclusions: multidisciplinary approach with ophthalmologists, hematologists and radiotherapy experts enhance good surgical and clinical results in the vast majority of cases.

Forma atípica de presentación del linfoma no Hodgkin en un paciente con sida / Atypical presentation of non-Hodgkin's lymphoma in a patient with AIDS

El linfoma no Hodgkin es la segunda neoplasia más frecuente en pacientes con sida. Sus formas clínicas sistémicas asociadas con el virus de inmunodeficiencia humana casi siempre tienen un alto grado una malignidad. La participación del sistema nervioso central es un hecho frecuente en pacientes con este tipo de linfoma. El objetivo es describir una forma atípica de presentación del linfoma no Hodgkin en un paciente con sida. Se informa acerca de un paciente de 28 años, VIH positivo, con linfoma no Hodgkin de células grandes B difuso que se presentó con parálisis aislada del III par craneal como principal manifestación inicial, la enfermedad progresó rápidamente y en pocos días tuvo un desenlace fatal. Se concluye que es necesario considerar el diagnóstico de linfoma no Hodgkin en pacientes con sida y parálisis del III par craneal, para de esta forma realizar un diagnóstico temprano e iniciar tratamiento oportuno debido a la rápida evolución y mal pronóstico de la enfermedad(AU)

Non-Hodgkin's lymphoma is the second most common neoplasm in patients with AIDS. Its systemic clinical forms associated with the human immunodeficiency virus almost always have a high degree of malignancy. Involvement of the central nervous system is a frequent occurrence in patients with this type of lymphoma. The purpose of the study is to describe an atypical presentation of non-Hodgkin's lymphoma in a patient with AIDS. A case is reported of a male 28-year-old HIV-positive patient with diffuse large B-cell non-Hodgkin's lymphoma who presented with isolated cranial nerve III palsy as the main initial manifestation. The disease progressed rapidly and had a fatal outcome some days later. It is concluded that it is necessary to consider the diagnosis of non-Hodgkin's lymphoma in patients with AIDS and cranial nerve III palsy, in order to make an early diagnosis and initiate timely treatment, in view of the rapid evolution and poor prognosis of the disease.(AU)

Uso de rituximabe no tratamento de linfoma linfoplasmocítico durante terapia de substituição renal contínua / Rituximab use for lymphoplasmacytic lymphoma during continuous renal replacement therapy

RESUMO A segurança e a eficácia do rituximabe em pacientes com comprometimento renal não foram estabelecidas, e o mesmo ocorre com os efeitos da hemodiálise nos níveis séricos de rituximabe. Atualmente, apenas alguns relatos de caso avaliaram o nível sérico de rituximabe antes e após a diálise. Não foram até aqui publicados dados relativos ao uso de rituximabe em pacientes sob terapia de substituição renal contínua. Os autores apresentam um caso referente a uma mulher com 59 anos de idade atendida com quadro de tetraparesia paraneoplásica. Ela foi admitida no serviço de medicina intensiva devido a hemorragia alveolar com insuficiência respiratória e lesão renal aguda, que necessitou da utilização de terapia de substituição renal contínua. Após os procedimentos diagnósticos, estabeleceu-se o diagnóstico de linfoma linfoplasmocítico. Deu-se início ao tratamento com rituximabe e ciclofosfamida. Os níveis de rituximabe foram determinados no soro e no dialisato. Não se encontrou qualquer nível de rituximabe no dialisato. A paciente faleceu após 2 meses no serviço de medicina intensiva por pneumonia nosocomial causada por Pseudomonas aeruginosa resistente a múltiplos fármacos.

ABSTRACT Rituximab safety and efficacy in patients with renal impairment have not been established, nor have the effects of hemodialysis on serum rituximab level. There are only a few published case reports assessing serum rituximab level pre- and postdialysis. No data have been published regarding the usage of rituximab in patients with continuous renal replacement therapy. The authors present a case of a 59-year-old female patient who presented with paraneoplastic tetraparesis. She was admitted to the intensive care unit due to alveolar hemorrhage with respiratory failure and acute kidney injury requiring continuous renal replacement therapy. After a diagnostic workup, the diagnosis of lymphoplasmacytic lymphoma was established. Therapy with rituximab and cyclophosphamide was started. Rituximab levels were determined in serum and dialysate. No rituximab was found in the dialysate. The patient died after 2 months in the intensive care unit from nosocomial pneumonia due to multidrug-resistant Pseudomonas aeruginosa.

Enfermedad linfoproliferativa asociada a artritis reumatoide: reporte de tres casos / Lymphoproliferative disease associated with rheumatoid arthritis: report of three cases

Las investigaciones en la última década han demostrado que el riesgo de desarrollar linfoma en pacientes con artritis reumatoide es el doble que el riesgo de la población general. Sin embargo, no se cuenta con datos de la magnitud de este problema en Cuba. Se presentan los casos de tres pacientes con diagnóstico de artritis reumatoide seropositiva tratadas con metotrexate, que durante su evolución desarrollaron linfoma no Hodgkin. Las pacientes recibieron quimioterapia de primera línea y alcanzaron remisión total con supervivencia de tres años hasta el momento. El diagnóstico de las enfermedades linfoproliferativas en pacientes con artritis reumatoide es un desafío; por lo que es necesario un elevado índice de sospecha que, en ausencia de marcadores fiables de linfomagénesis, permita el manejo oportuno de estos pacientes(AU)

Research in the last decade has shown that the risk of developing lymphoma in patients with rheumatoid arthritis is twice the risk of the general population. However, there is not data on the magnitude of this problem in Cuba.We present the cases of three patients with a diagnosis of seropositive rheumatoid arthritis treated with methotrexate who during their evolution developed non-Hodgkin's lymphoma.The patients received first-line chemotherapy and they achieved total remission with three-year survival so far.The diagnosis of lymphoproliferative diseases in patients with rheumatoid arthritis is a challenge; therefore, a high index of suspicion is necessary that, in the absence of reliable markers of lymphomagenesis, allows the timely management of these patients(AU)

Linfoma no Hodgkin de amígdalas en un paciente con lupus eritematoso sistémico / Non-Hodgkin's lymphoma of tonsils in a patient with systemic lupus erythematous

Introducción: las enfermedades reumáticas aumentan el riesgo de aparición de distintas comorbilidades y estado de salud inadecuado en los pacientes. Dentro de estas comorbilidades las más peligrosas, por la frecuencia que se producen y por el desenlace final de las mismas lo constituyen las enfermedades neoplásicas. Objetivos: socializar los elementos clínicos, de laboratorio e histopatológicos que permiten la sospecha clínica y el diagnóstico de linfoma no Hodgkin en pacientes con enfermedades reumáticas. Caso clínico: paciente femenina de 54 años de edad, con diagnóstico de lupus eritematoso sistémico y síndrome de Sjögren secundario que acude con manifestaciones clínicas dadas por sudores nocturnos profusos, toma del estado general, fiebre vespertina y adenopatías cervicales. Se le realiza el diagnóstico de linfoma no Hodgkin en amígdala derecha. Conclusiones: las enfermedades reumáticas aumentan el riesgo de aparición de enfermedades neoplásicas. El seguimiento periódico, la adherencia farmacológica y el monitoreo constante de manifestaciones generales y elementos de sospecha de procesos malignos, son las acciones fundamentales que se pueden realizar para prevenir o diagnósticas precozmente la aparición de afecciones neoplásicas en pacientes reumáticos(AU)

Introduction: rheumatic diseases increase the risk of the appearance of different comorbidities and inadequate health status in patients. Within these comorbidities the most dangerous, by the frequency that occur and by the final outcome of them are neoplastic diseases. Objectives: to socialize the clinical, laboratory and histopathological elements that allow clinical suspicion and the diagnosis of non-Hodgkin's lymphoma in patients with rheumatic diseases. Case report: A 54-year-old female patient with a diagnosis of systemic lupus erythematous and secondary Sjogren's syndrome who presented with clinical manifestations due to profuse nocturnal sweats, general condition, afternoon fever and cervical lymphadenopathy. He is diagnosed with non-Hodgkin's lymphoma in the right amygdala. Conclusions: rheumatic diseases increase the risk of the appearance of neoplastic diseases. The periodic follow-up, the pharmacological adherence and the constant monitoring of general manifestations and elements of suspicion of malignant processes, are the fundamental actions that can be performed to prevent or early diagnosis the appearance of neoplastic affections in rheumatic patients(AU)

Oligoartritis, paniculitis y pioderma gangrenoso como manifestaciones de un Linfoma no Hodgkin / Oligoarthritis, panniculitis and pyoderma gangrenosum associated with non-Hodgkin lymphoma: report of one case

An assortment of clinical and laboratory abnormalities may occur as paraneoplastic syndromes in lymphomas. Rheumatological and dermatological manifestations such as paraneoplastic arthritis and pyoderma gangrenosum must be underscored. We report a 28 years old woman who developed pyoderma gangrenosum and two years later presented with arthritis of knees and ankles associated with panniculitis interpreted as erythema induratum that was pathologically confirmed. She developed a reactivation of pyoderma gangrenosum, that was refractory to treatment. Complementary studies showed a pulmonary nodule and a right paravertebral mass with involvement of the psoas muscle. Biopsies of both masses and a new pathological skin study demonstrated a large B-cell non-Hodgkin's lymphoma.

Linfoma gástrico no Hodgkin perforado / Perforated gastric non-Hodgkin lymphoma

Los linfomas son tumores sólidos del sistema linfático y se subdividen en linfomas de Hodgkin y no-Hodgkin. Los tumores no Hodgkin pueden originarse en tejidos no ganglionares como el tubo digestivo y son considerados primarios cuando el compromiso extranodal es igual o superior al 75% con relación al compromiso nodal. Los linfomas extranodales gastrointestinales representan del 1% al 4% de los tumores del tracto digestivo y del 10 al 15% de todos los linfomas no Hodgkin. El estómago es el sitio extranodal más común de los linfomas. Presentamos el caso clínico de un paciente varón sexagenario natural de Chiclayo que se realiza una endoscopía particular por síntomas inespecíficos de dispepsia y sólo se informa gastritis eritematosa y al ser admitido en nuestra institución se le diagnostica por endoscopía, marcadores bioquímicos y anatomopatología como un linfoma gástrico no Hodgkin perforado

Lymphomas are solid tumors of the lymphatic system and these are divided into Hodgkin's and non-Hodgkin lymphoma. Non-Hodgkin tumors may originate from non-nodal tissues such as the gastrointestinal tract and they are considered primary when extranodal involvement is equal to or greater than 75% according to the nodal involvement. Extranodal gastrointestinal lymphomas represent 1% to 4% of tumors of the digestive tract, and 10 to 15% of all non-Hodgkin lymphomas. The stomach is the most common extranodal lymphomas site. We present the clinical case of a sexagenarian male natural of Chiclayo who had an upper GI endoscopy for non-specific symptoms of dyspepsia that only reports gastritis and when admitted to our institution is diagnosed by endoscopy, biochemical markers and pathology as a perforated gastric non-Hodgkin lynphoma

Eficacia y seguridad de ibrutinib en el tratamiento de pacientes con diagnóstico de linfoma de células del manto, con al menos dos líenas de tratamiento previo / Efficacy and safety of ibrutinib in the treatment of patients diagnosed with mantle cell lymphoma, with at least two previous treatment regimens

INTRODUCCIÓN: Antecedentes: El presente dictamen expone la evaluación de tecnología de la eficacia y seguridad del uso de ibrutinib en el tratamiento de pacientes con diagnóstico de linfoma de células del manto. Aspectos Generales: El linfoma de células del manto (LCM) es un tipo muy agresivo de linforma no-Hodgkin que se origina por la malignización de los linfocitos B en el margen externo del folículo de un ganglio linfático o zona del manto y se caracteriza por la translocación cromosomal t)11,14) y la sobre-expresión de la ciclina D1(1). Su incidencia se estima en0.51 casos por cada 100,000 habitantes, representando el 2-10% de todos los linforma no-Hodgkin. Epidemiológicamente se caracteriza por ser más frecuente en varones entre los 60-68 años de edad. Tecnología Sanitaria de Interés: Ibrutinib, un inhibidor covalente de primera generación de la tirosina quinasa de Bruton (BTK, por sus siglas en inglés(, es una molécula pequeña que se une de manera irreversible al residuo 481 de cisteína en el dominio de la quinasa de la tirosina de Bruton de las células B. Adicionalmente, ibrutinib también se puede unir a otros dominios de quinasa que contienen un residuo de cisteína homólogo, tales como HER2, BLK y JAK3 entre otros. El linforma no-Hodgkin de células del manto es un tipo de neoplasia de células B. La quinasa de Bruton se encuentra por debajo de la cascada de señalización del receptor de las células B. La señal enviada por el receptor de dichas células, ya sea dependiente o independiente de antígenos, es considerada una de los principales mecanismos detrás de la progresión de este tipo de neoplasias, ya que juega un rol critico en la supervivencia y proliferación de las células B. METODOLOGÍA: Estrategia de Búsqueda: Se realizó una búsqueda de la literatura con respecto a la eficacia y seguridad del uso de ibrutinib para el tratamiento de LCM en pacientes que han progresado a más de dos lineas de tratamiento previo. Esta búsqueda se realizó utilizando las bases de datos MEDLINES, EMBASE, SCOPUS, WEB OF SCIENCE, CINAHL, COCHRANE y TRIP DATABASE. Adicionalmente, se hizo una búsqueda dentro de la información generada por las principales agencias de tecnologías sanitarias que realizan revisiones sistemáticas (RS), evaluación de tecnologías sanitarias (ETS) y guías de práctica clínica (GPC). RESULTADOS: Sinopsis de la Evidencia: Se realizó la búsqueda bibliográfica y de evidencia científica hasta noviembre 2016 que sustente el uso de ibrutinib en el tratamiento de LCM para pacientes que han recibido dos o más líneas de tratamiento previo. CONCLUSIONES: En el presente dictamen se evaluó la evidencia científica publicada hasta noviembre 2016 en relación al uso de ibrutinib en pacientes con LCM que han recibido más de dos líenas de tratamiento. El Instituto de Evaluación de Tecnologías en Salud e Investigación (IETSI) no aprueba el uso de ibrutinib para el tratamiento de LCM en pacientes con al menos dos líneas de tratamiento.

Neurolinfomatose de nervos cranianos e plexos braquial e lombossacro em um paciente com linfoma não Hodgkin: relato de caso / Neurolymphomatosis of cranial nerves and brachial and lumbosacral plexuses in a patient with non-Hodgkin lymphoma: a case report

Neurolinfomatose (NL) corresponde à infiltração do sistema nervoso periférico por células neoplásicas, sendo a manifestação neurológica menos comum dos linfomas, principalmente do Linfoma Não Hodgkin (LNH). A infiltração pode ocorrer em diversos níveis, como junções neuromusculares, nervos periféricos ou raízes nervosas, sendo que a maioria dos pacientes possui múltiplos sítios envolvidos, incluindo raízes nervosas espinhais, nervos cranianos e plexos nervosos. Neste relato, descrevemos um caso de LNH, em paciente HIV positivo, com NL em nervos cranianos e plexos braquial e lombossacro bilaterais, com sintomas de paresia e parestesia de membros inferiores e membro superior esquerdo, ptose, midríase e estrabismo divergente em globo ocular direito, arreflexia em membros inferiores e marcha atáxica. Nos exames de imagens, foram observadas alterações compatíveis com espessamento de raízes nervosas da cauda equina, bem como hiperssinal no III par craniano à direita e espessamento do V par craniano à direita. A partir da análise do líquido cefalorraquidiano e da exclusão de outras hipóteses diagnósticas, houve forte suspeita de NL. O paciente apresentou melhora parcial do quadro após corticoterapia, sendo encaminhado para tratamento oncológico. A possibilidade de infiltração linfomatosa em pacientes com quadro de mono ou polineuropatia deve ser sempre lembrada nos pacientes com LNH, podendo ser a primeira ou a única manifestação clínica da enfermidade. Um diagnóstico precoce é fundamental para a melhora do prognóstico (AU)

Neurolymphomatosis (NL) corresponds to the infiltration of the peripheral nervous system by neoplastic cells, being the less common neurological manifestation of lymphomas, mainly Non-Hodgkin's Lymphoma (NHL). Infiltration can occur at several levels, such as neuromuscular junctions, peripheral nerves or nerve roots, with most patients having multiple sites involved, including spinal nerve roots, cranial nerves, and nerve plexuses. In this report we describe a case of NHL in an HIV positive patient with NL in cranial nerves and bilateral brachial and lumbosacral plexuses, with symptoms of paresis and paresthesia of the lower limbs and left upper limb, ptosis, mydriasis and divergent strabismus in the right eyeball, areflexia in lower limbs and ataxic gait. In the imaging studies, alterations consistent with thickening of the nerve roots of the cauda equina were observed, as well as hypersignal in the right cranial nerve III and thickening of the right V cranial nerve. From an analysis of the cerebrospinal fluid and the exclusion of other diagnostic hypotheses, there was a strong suspicion of NL. The patient presented partial improvement after corticotherapy and was subsequently referred for cancer treatment. The possibility of lymphomatous infiltration in patients with mono or polyneuropathy should always be remembered in patients with NHL, which may be the first or only clinical manifestation of the disease. Early diagnosis is crucial for improving the prognosis (AU)

Linfoma no hodgkiniano parecido al Burkitt / No hodgkin lymphoma burkitt-like

El linfoma no hodgkiniano parecido al Burkitt es considerado una neoplasia de células B altamente agresiva, con un alto índice de proliferación. Las presentaciones en forma de masas tumorales abdominales no son muy frecuentes y están poco documentadas en la literatura. Se reporta un caso poco usual de un paciente adulto joven con linfoma no hodgkiniano parecido al Burkitt, con infiltración del colon derecho, tratado con poliquimioterapia asociada a la administración de anticuerpo monoclonal anti-CD20, con lo que se alcanzó la remisión completa de la enfermedad. Posteriormente esta respuesta se consolidó con esquemas intensivos de quimioterapia y trasplante de progenitores hematopoyético autólogo. Actualmente se mantiene asintomático y sin tratamiento(AU)

The Burkitt-like lymphoma is considered a highly aggressive B-cell lymphoma, with a high proliferative rate. Presentation with extensive mass intestinal involvement is rare and poorly documented in the literature. We report the case of a young adult with the Burkitt-like lymphoma, and presenting extensive infiltration of the right colon, who receives chemotherapy treatment associated with administration of anti-CD20 monoclonal antibody, achieves complete remission of the illness and consolidation with intensive chemotherapy with autologous stem cell transplantation. Currently the patient is asymptomatic and without treatment(AU)

Usefulness of Flow Cytometric Analysis for Detecting Leptomeningeal Diseases in Non-Hodgkin Lymphoma

BACKGROUND: The clinical usefulness of flow cytometry (FCM) for the diagnosis of leptomeningeal diseases (LMD) in non-Hodgkin lymphomas has been suggested in previous studies but needs to be further validated. With this regards, we evaluated the use of FCM for LMD in a series of Korean patients with non-Hodgkin lymphoma. METHODS: FCM and cytomorphology were conducted using samples obtained from clinically suspected LMD patients, follow-up LMD patients, and those with high risk of developing tumorigenic diseases. We then compared results of FCM and cytomorphology. In total, 55 and 47 CSF samples were analyzed by FCM and cytomorphology, respectively. RESULTS: Of the samples analyzed, 25.5% (14/55) and 12.8% (6/47) were positive by FCM and cytomorphology, respectively. No samples were determined as negative by FCM but positive by cytomorphology. Seven patients were positive only by FCM and negative by cytomorphology, and six among them were clinically confirmed to have LMD either by follow-up cytomorphology or imaging study. CONCLUSIONS: We observed a high detection rate of tumor cells by FCM compared with cytomorphology. FCM study can be useful in early sensitive detection of LMD.

Pneumonia due to Rhodococcus equi in a non-Hodgkin's lymphoma patient: case report

The authors reported a lung infection by Rhodococcus equi in a 25 years-old male patient admitted to hospital with cough, dyspnea, fever, and previous diagnosis of pleural effusion. R. equi was isolated from pleural fluid and the patient acquired nosocomial infection by Acinetobacter baumannii, isolated from chest drain. The patient was treated with antibiotics. During hospitalization, he was diagnosed with non-Hodgkin lymphoma of precursor T-cell lymphoblastic lymphoma subtype in biopsy of pleura. After undergoing surgery for pulmonary decortication for drain empyema, the patient died due to septicemia(AU)

Los autores informan de una infección pulmonar por Rhodococcus equi en un paciente masculino de 25 años que fuera hospitalizado con tos seca, disnea, fiebre y diagnóstico previo de derrame pleural. R. equi se aisló del líquido pleural y el paciente adquiere una infección nosocomial con Acinetobacter baumannii aisladas de un drenaje torácico. El paciente recibió tratamiento con antibióticos y, durante la hospitalización, fue diagnosticado linfoma no Hodgkin subtipo de linfoma linfoblástico de precursoras de células T en la biopsia pleural. Después de la cirugía para decorticación pulmonar para la fuga de empiema, el paciente falleció debido a una septicemia(AU)

Linfoma de Hodgkin y no Hodgkin durante la gestación: a propósito de dos casos / Hodgkin's and non-Hodgkin during pregnancy: report of two cases

Las neoplasias hematológicas en el embarazo conllevan un gran riesgo para la madre y el feto. El linfoma, Hodgkin (LH) y no Hodgkin (LNH), es la cuarta causa más frecuente de cáncer diagnosticado en el embarazo. El tipo más frecuente es el LH, mientras que la incidencia de LNH es muy baja. Presentamos dos casos de gestantes de 29 y 25 años, diagnosticadas en el segundo trimestre de la gestación de LNH mediastínico de células B y LH tipo esclerosis nodular respectivamente. Ambas fueron tratadas con quimioterapia desde el diagnóstico hasta dos semanas antes del parto, con buen resultado perinatal.

Haematological cancer in pregnancy poses a substantial risk to both, mother and fetus. Lymphoma, including Hodgkin's lymphoma (HL) and Non-Hodgkin's lymphoma (NHL), is the fourth most frequent malignancy diagnosed during pregnancy. The most common type of lymphoma in this setting is HL, and the incidence of pregnancy associated NHL is very low. In this report we describe two cases of a 29-year-old woman and a 25-year-old woman both in the second trimester of pregnancy, diagnosed with mediastinal B-cell NHL and nodular-sclerosis HL respectively. They were managed with chemotherapy since the diagnosis as far as two weeks before the delivery, both with a successful fetal outcome.

Synchronous Hepatocellular Carcinoma and B-Cell Non-Hodgkin's Lymphoma in Chronic Hepatitis C Patient / 대한소화기학회지

Hepatitis C virus (HCV) is one of the main viral causes of hepatocellular carcinoma (HCC) and is associated with lymphoproliferative disorder such as non-Hodgkin's lymphoma (NHL). However, there are only few case reports on concomitantly induced NHL and HCC by HCV. Herein, we report a case of synchronous NHL and HCC in a patient with chronic hepatitis C which was unexpectedly diagnosed during liver transplantation surgery. This case suggests that although intrahepatic lymph node enlargements are often considered as reactive or metastatic lymphadenopathy in chronic hepatitis C patients with HCC, NHL should also be considered as a differential diagnosis.

Tratamento odontológico prévio a transplante de células tronco-hematopoiéticas: um relato de caso / Dental treatment prior to hematopoietic stem cell transplant: a case report

O linfoma é uma neoplasia malígna que se desenvolve nos gânglios linfáticos e uma possível abordagem terapêutica para esta doença é o transplante de medula óssea. Sob condições de imunossupressão, todo foco infeccioso pode ser ativado e, em função disto, toda infecção ativa em pacientes pré-transplantes de células hematopoiéticas deve ser erradicada previamente, para prevenir ou reduzir riscos de complicações sistêmicasnestes pacientes. Objetivo: Relatar um caso de atendimento odontológico a um paciente com necessidade premente de transplante de células tronco-hematopoiéticas, acometido de Linfoma não-Hodgkin.

Prevalence and aetiology of anaemia in lymphoid malignancies.

Background. We prospectively studied the prevalence, type and causes of anaemia in newly diagnosed patients with lymphoid malignancies. Methods. Between January 2007 and June 2008, a total of 316 newly diagnosed, consecutive patients (aged 15 years or above) of Hodgkin lymphoma, non-Hodgkin lymphoma and chronic lymphocytic leukaemia with anaemia (haemoglobin <11 g/dl), were analysed to determine the prevalence and a subgroup of 46 patients was analysed for the cause of anaemia. Results. Hodgkin lymphoma, non-Hodgkin lymphoma and chronic lymphocytic leukaemia were the diagnoses in 81 (25.8%), 203 (64.7%) and 30 (9.6%) patients, respectively. Anaemia was present in 134 patients (42.4%). Anaemia of chronic disease was present in 33/46 (71.7%) and iron deficiency in 18/46 (39.1%) patients. Vitamin B12 and/or folate deficiency was detected in 10/46 (21.7%) patients (B12 deficiency alone in 7, folate deficiency alone in 1 and combined B12 and folate deficiency in 2). Autoimmune haemolytic anaemia was detected in 5/46 (10.9%) although direct Coombs test was positive in 17/46 (37%) patients. Among patients with Hodgkin lymphoma and non-Hodgkin lymphoma, anaemia due to bone marrow involvement was present in 16/40 (40%). In most patients with bone marrow involvement, anaemia was due to other causes. In only 3 patients, anaemia was attributable to bone marrow involvement alone. Anaemia was multifactorial in 18/46 (39.1%) patients. Nutritional deficiency alone or in combination was present in 22/46 (47.8%) patients. Conclusion. Anaemia is common in lymphoid malignancies at initial presentation. Besides managing anaemia of chronic disease and bone marrow involvement, nutritional and autoimmune causes should be ruled out.

Linfomatosis intravascular cerebral como causa de demencia rápidamente progresiva: reporte de un caso / Cerebral intravascular lymphomatosis as cause of subacute dementia: report of a case

Cerebral Intravascular Lymphomatosis is a type of non Hodgkin Lymphoma, generally composed with B cells, its ocurrence is infrequent, clinically progressive and has a fatal course. Vascular damage is related with tumoral infiltration and small caliber occlusion, with results in multi infarcts. Neurological symptoms and signs are frequently the first clinical manifestation, which include sub acute encephalopathy, cognitive impairment, delirium, aphasia, hemipharesis, visual disturbances, paraplegia, paresthesia and cranial nerves involvement. MRI shows images of vasculitis from CNS. Cerebral Intravascular Lymphomatosis must be considered in differential diagnosis of rapid and subacute dementias, and clinical cases with small vessel recurrent multi infarct of unusual etiology. We present the clinical case of a patient with rapid progressive dementia and systemic disease manifestation. The CNS involvement was characterized as a subacute encephalopathy, with confusion and agitation, seizures, motor disturbances, bilateral plantar extensor reflexes and cerebellar signs. The clinical symptomatic course was progressive, with weight loss and fluctuant fever. The patient had a fatal course after he was treated with Methylprednisolone. Postmortem pathologic examination revealed a diffuse non Hodgkin lymphoma of B cells, intravascular variant, with brain compromise, cerebellum, suprarenal glands, pancreas, myocardium, thyroid gland, lung kidney and the lever...

La linfomatosis intravascular cerebral es un tipo de Linfoma no Hodgkin generalmente de células B, de presentación infrecuente, curso clínico progresivo y fatal. El daño vascular es producto de oclusión de vasos de pequeño calibre por infiltración tumoral, con resultado de múltiples infartos. Las manifestaciones neurológicas suelen ser la forma de presentación clínica inicial, caracterizadas por un amplio espectro que incluye encefalopatía subaguda, deterioro cognitivo, delirio, afasia, hemiparesia, trastornos visuales, paraplejia, parestesias y compromiso de pares craneanos. Los estudios de RNM evidencian alteraciones indistinguibles de las vasculitis del SNC. La linfomatosis intravascular debe considerarse en el diagnóstico diferencial de las demencias rápidamente progresivas y en los cuadros de multi infarto cerebral de pequeño vaso de etiología inusual y recurrente. Se presenta el caso de un paciente con demencia rápidamente progresiva, con manifestaciones neurológicas de deterioro cognitivo y enfermedad sistémica. El compromiso del SNC se expresó como encefalopatía subaguda con confusión, agitación, y crisis convulsivas, trastornos motores con reflejo cutáneo plantar extensor bilateral y compromiso cerebeloso, de curso clínico sintomático progresivo, con baja de peso y fiebre fluctuante. El paciente fue sometido a tratamiento con metilprednisolona a pesar del cual falleció. El estudio necrópsico demostró alteraciones por Linfoma no Hodgkin difuso de células B, variante intra vascular, con compromiso del cerebro, cerebelo, glándulas suprarrenales, páncreas, miocardio, tiroides, pulmón riñón e hígado...